Table 33Summary of multivariable analyses in single-arm studies of 3DCRT

StudyNo. PtsSettingSite% Stage 0/I/II% Stage III/IVOutcomeUnivariate Predictorsp ValueMultivariable Predictorsp Value
Zheng et al. 2005[154] (07/97–03/03)86ReRT (100) chemotherapy unclear (53)NPH≥51 (?balance)OS
LFF
MLT
Age
Gender
Histologic type
Mean dose primary tx
Volume of primary tx irradiated
T stage of recurrence
GTV volume of recurrence
Interval from completion of first course of RT to dx of recurrence
Pre-existing late toxicities from previous
RT, CT, simultaneous regional recurrence and dose conformity index.
T stage and GTV for OS (p<.01), LFF (p<.01 and p=.03), and MLT (p<.01).

Advanced T stage and large GTV volume were associated with poor OS and LFF and high risk of MLT.
T stage and GTV volumeT stage significant for OS (p<.01) and LFF (p=.01).

GTV volume significant for MLT (p=.04).
Ikushima et al. 2008[140] (1999–2002)40Concurrent chemotherapy (100)OC100SurvivalAge.32Age0.39
Sex.53Sex0.79
Stage.86Local response to tx0.12
Local response to tx.04Mode of tumor invasion0.14
Mode of tumor invasion.03
LN mets.01LN mets0.15
Cheng et al. 2006[138] (04/90–12/02)630Primary RT (#NR) Concur- rent chemotherapy (93) Adjuvant chemotherapy (76)NPH≥65.2 (?balance)Risk of LR recurrenceT stageAge >40 vs. ≤40.03
 T3 vs. T1–T2.02LDH ≥410 vs. <410.002
 T4 vs. T1–T2.0002Histology (WHO type I-II vs. III).002
Primary tumor size ≥4 cm.002Anatomic site involved ≥2 vs. <2.0004
Parapharyngeal space extension.01
Sphenoid floor invasion<.0001
Clivus marrow infiltration.002
Clivus cortex invasion<.0001
Prevertebral muscles invasion<.0001
Petrous bone invasion.01
Sphenoid sinus invasion.001
Foramen lacerum invasion.001
Foramen ovale invasion.0003
Cavernous sinus invasion.0004
Intracranial invasion.002
Infratemporal fossa invasion.005
Ethmoid sinus invasion.006
Hard palate invasion.02
Anatomic grouping #2 with two or more anatomic sites involved<.0001
Anatomic grouping #3 with one or more anatomic sites involved.0001
Anatomic grouping #5 with one or more anatomic sites involved.02
Lau et al. 2006[143] (09/00–12/02)56Adjuvant chemotherapy (100)MIX7.192.8OSAge at dx Initial Hb Karnofsky PS Receiving <50% planned chemotherapy T and N stage

Overall stage Primary tumor site
Significant






NS
Amount of CT received N classificationSignificant
DSSAge at dx Initial Hb Karnofsky PS T and N stage

Amount of chemotherapy received Overall stage Primary site
Significant




NS

LRRFSAge at dx Karnofsky PS Amount of chemotherapy received T and N stage

Initial Hb Overall stage Primary site
Significant




NS

Sze et al. 2004[153] (11/98–06/01)308Primary RT (58.4)
Concur- rent chemotherapy (37.7)
Neoad-juvant chemotherapy (3.9)
NPH≥56.5 (?balance)LFFR
PFS
OS
GTV-P

(using T stage [T1–2 vs. T3–4] as a covariate, GTV-P remained an independent prognostic factor for LFFR. When adjusted for group stage, age, gender, CT and fractionation scheme=NS)
<.05
<.05
<.05

From: Results

Cover of Comparative Effectiveness and Safety of Radiotherapy Treatments for Head and Neck Cancer
Comparative Effectiveness and Safety of Radiotherapy Treatments for Head and Neck Cancer [Internet].
Comparative Effectiveness Reviews, No. 20.
Samson DJ, Ratko TA, Rothenberg BM, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.